Rexulti

Business news, market intelligence, and global industry analysis.

The Latest

Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?

realme Buds T310 in Agile White: top true wireless earbuds under ₹2,000

realme Buds T310 review: Are these the best budget ANC earbuds under ₹2,000?

Why support-platform strategy may become a differentiator in schizophrenia treatment markets

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Vyepti and Rexulti power Lundbeck (CPH: LUN) to raise 2025 guidance after 22% adjusted EBITDA surge

Lundbeck lifts 2025 guidance as Vyepti and Rexulti drive 22% EBITDA growth. Explore the neuroscience-focused strategy powering its latest earnings surge.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

November 12, 2025